Agreement between seroprevalence- and model-based estimates of COVID-19 burden
Nana Owusu-Boaitey, Lucas Böttcher, Gideon Meyerowitz-Katz, Jonathan Howard, David H Gorski, Lonni Besançon, Anton Barchuk · 2026
Read Agreement between seroprevalence- and model-based estimates of COVID-19 burden by Nana Owusu-Boaitey, Lucas Böttcher, Gideon Meyerowitz-Katz, Jonathan Howard, David H Gorski, Lonni Besançon, Anton Barchuk (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13250881.txt.
Description
Owusu-Boaitey and colleagues revisit whether early COVID-19 models or early antibody surveys better captured the pandemic's true size. Their 2026 Global Health Action discussion paper explains how seroprevalence studies, which track infection antibodies, first suggested lower fatality risks. Some early surveys undercounted the risk for children and for lower-income countries.
Later antibody studies that reached the right groups, plus corrections for known biases, lined up with the early modeling results. The authors say this agreement vindicates the models that guided policy at the time. They urge health authorities to tell the public plainly about that success and about the limits of early survey work. Clearer lessons, they argue, will help the public judge risks in future pandemics.
Catalog record
| CREATOR | Nana Owusu-Boaitey, Lucas Böttcher, Gideon Meyerowitz-Katz, Jonathan Howard, David H Gorski, Lonni Besançon, Anton Barchuk |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |